📰 Multiple System Atrophy News
Page 19 - Multiple System Atrophy News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Multiple System Atrophy. Real-time updates on events, politics, business and more.
October 13, 2022
Kathrin LaFaver, MD, and Indu Subramanian, MD, discuss updates on Parkinsons disease, including highlights of the 2022 International Congress of Parkinsons Disease and Movement Disorders.
October 13, 2022
Australia now open for study of rare, rapidly progressive Parkinsonian Disorder MELBOURNE, Australia and SAN FRANCISCO, Oct. 13, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that it has received approval in Australia from the St. Vincent's Hospital Melbourne...
October 12, 2022
BOSTON and ATLANTA, Oct. 12, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical compan...
September 26, 2022
/PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying...
September 26, 2022
- Wearable sensors strongly correlated with clinical scales on motor impairment - - bioMUSE Study Validates Use of Wearable Sensors for Alterity's Ong
September 26, 2022
– Wearable sensors strongly correlated with clinical scales on motor impairment – – bioMUSE Study Validates Use of Wearable Sensors...
September 21, 2022
/PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor...
September 21, 2022
/PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor...
September 21, 2022
BOSTON and ATLANTA, Sept. 21, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical compa...
September 21, 2022
BOSTON and ATLANTA, Sept. 21, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinsons disease, Parkinson...